CC
CLBT icon

Centiva Capital’s Cellebrite CLBT Stock Holding History

Centiva Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,500
Closed -$27.7K – 2114
2024
Q1 		$27.7K Buy
+2,500
New +$25.5K ﹤0.01% 1668

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Centiva Capital's CLBT Position: Q1 2026 in Review

Centiva Capital increased its Cellebrite (CLBT) stake by 131% in Q1 2026, buying an estimated $214K and bringing the position to 25,058 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1003.

Centiva Capital first reported a position in CLBT in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.94M in Q2 2024. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Centiva Capital held 25,058 shares of Cellebrite worth $345K as of Q1 2026.
  • Centiva Capital bought 14,216 Cellebrite shares in Q1 2026, an estimated $214K.
  • Cellebrite made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #1003 holding.
  • Centiva Capital first reported a position in Cellebrite in Q4 2023 and has held it in 6 quarters since.
  • Centiva Capital's Cellebrite position peaked at $1.94M in Q2 2024.
  • 220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.